Jupiter Neurosciences secures up to $20 million in flexible financing agreements.

Jupiter Neurosciences has entered into agreements with Yorkville Advisors Global for up to $20 million in flexible financing. The funding will support a Phase 2 Parkinson's trial and accelerate the growth of the Nugevia product line. The financing is designed to provide Jupiter with the necessary resources to advance its CNS disorder treatments and expand its consumer longevity market offerings.